| Author(s) |
Eric BASEILHAC Brigitte DORMONT Maurice-Pierre PLANEL |
| Publication type | Synthesis |
Breakfast debate on December, 13th 2018
The regulation of drug prices is largely structured by a scissor effect between two major challenges: access to innovation for all and controlling healthcare expenditure. The current context of rapid acceleration in therapeutic innovation calls into question the principles and criteria adopted hitherto by regulation. Is it still relevant to think in terms of a closed envelope of healthcare expenditure? How can we assess the benefits of eradicating a disease through the use of a drug, or the costs of transforming a fatal disease into a chronic one? What determines the fair price of a drug?
This document provides a summary of the presentations and discussions that led the breakfast on the theme of "The price of medicines" organised by the Governance and Regulation Chair on 13 December 2018.
